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Gene therapy belongs to the most rapidly
developing fields of modern medicine what is
closely related to the achievements in genetic
engineering particularly to the development of the
DNA (gene) transfer intoeucariotic cells
technology. During last fiver years 120 clinical
protocols of human gene therapy have been
designed which involve about 600 patients. About
half of the protocols are currently in the phase I or
II clinical trials. In Europe 6 out of 15 approved
clinical protocols including one in Poland are
currently curried out. Majority of protocols (60%)
concern neoplastic diseases, 25% hereditary
genetic disorders, 10% AIDS and remaining 5%
rheumatic or vascular diseases.
Gene therapy may be defined as an
alteration of the cell phenotype by insertion of the
"correct" or removal of "incorrect" genetic
information or modification of normal cell by
introduction of a new information in order to
control or threat the disease. Cells may be
genetically modified ex vivo (cellular gene
therapy) or in vivo (gene therapy).
The basis of gene therapy form vectors
introducing DNA into target cells. Two types of
vectors, viral and non-viral vectors are currently
applied in human trails. Non-viral vectors are
cationic Iyposomes. Viral vectors are based on
retroviruses, adenoviruses, adeno-associated
viruses and herpesviruses. In two clinical
protocols "naked" DNA is injected into cells. In
two/third of protocols retroviral vectors are
employed.
Number of hereditary disorders is caused
by a single gene defect what leads to the
malformation of the particular metabolic pathway.
In such cases therapy would be based on the
transfer of functional copy of the gene into
defective cell. However, highest expectations of
the development of the gene therapy are related
to the neoplastic diseases. Cancer therapy clinical
protocols being in trial are based on 5 strategies:
(i) genetic cellular cancer vaccines; (ii) intro-
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duction of major histocompability complex (MHC)
antigens directly into tumor cells in situ; (iii)
introduction of suicide genes into tumor cells in
situ and activation of suicide mechanisms; (iv)
introduction into tumor cells of suppressor genes
and/or anti-oncogenes and blocking of oncogenes
expression; (v) introduction of multidrug
resistance genes (MDR) into bone marrow cells in
order to protect them from high dose
chemotherapy.
The larger number of cancer gene
therapy clinical protocols deals with cancer
cellular genetic vaccines. Strategy of these
vaccines is to deliver locally together with cancer
cells factors (most frequently. cytokines) which will
induce anti-cancer specific and non specific
responses by enhancing presentation of tumor
antigens or by providing costimulatory signals for
immune system. Cytokines might be provided by
transfer of their genes into autologous tumor cells,
allogeneic cell lines or ,fibroblasts which will be
then mixed with autologous tumor cells.
Autologous cellular genetic vaccines are prepared
by ex vivo transfer of cytokine genes into patienfs
own tumor cells cultured in vitro, which are then
irradiated and subcutaneously injected back to the
patient. Basis of allogeneic vaccines form cancer
established cell lines which are transduced with
genes coding particular cytokine or other factors.
In the case of melanoma HLA-A1 and HLA-A2
positive cell lines which express MAGE and
MART antigens are selected, . Allogeneic
vaccines in certain circumstances, such as
problems with obtaining cancer tissue from the
patient, might be alternative to autologous
vaccines. In general preparation of autologous
vaccines is difficult while allogeneic vaccines are
believed to be less effective. Accordingly, efforts
are undertaken to develop mixed vaccines. They
comprise of autologous tumor cells which are
isolated from cancer tissue and frozen without
genetic modification and cells producing
cytokines. Autologous fibroblasts or allogeneic cell
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lines (as developed in our Department) modified
to secrete cytokines may be employed.
Interleukin 6 (IL-6) displays its activity
through a membrane specific receptor composed
of two subunits a (gp80, CD126) anq r.. (gp130,
CD130)[Mackiewicz et aleds, 1995]. IL-6 binds to
subunit a (without transducing a signal) and then
attracts two molecules of subunit r.., what leads to
signal transduction. Soluble form of gp80 (sIL-
6Ra) acts agonistically with IL-6. IL-6/sIL-6Ra
complex displays different biological activities than
IL-6 alone since it may activate cells which
express only gp130, while IL-6 requires both
subunits. Transfer of IL-6 and s1L-6Ra genes into
murine melanoma cells results in the inhibition of
tumor growth and metastases formation.
Immunization of mice with IL-6/sl L-6Ra
transduced melanoma cells induced long lasting,
specific anti-melanoma immunity. Based on the
preclinical studies clinical protocol for Immuno-
gene therapy of human melanoma was designed
in our Department [Mackiewicz et ai, 1995]. In
January 1995 phase I clinical trial was initiated.
Until now 8 patients with IV clinical degree of
melanoma received genetic vaccine. 2.5 x 107
autologous cells were mixed with the same mount
of allogeneic cells modified to secrete IL~6 and slL-
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6R and injected to patients according to following
schedule: 4 injections in two weeks intervals, 3
injections in one month intervals and 3 injections
in
two months intervals. During therapy no toxic
effects were observed. Induction of specific and
non-specific anti-melanoma
response was observed. Currently the trial enters
phase II. Optimalization of doses and
immunization schedule as well as verification of
patients eligibility will be carried out. Moreover,
clinical effects of applied therapy will be
monitored.
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